Response to Letter to the Editor: Re: "A novel technique of NexoBrid™ application to burns on the hands" by L.R. Springford, H. Creasy, T. Cubison, B. Dheansa [Burns 2017;43:1129-39].

Autor: Rigueros Springford L; Queen Victoria Hospital, Department of Burns and Plastic Surgery, Burns Unit, East Grinstead, RH19 3DZ, United Kingdom. Electronic address: laurie.springford@nhs.net., Creasy H; Queen Victoria Hospital, Department of Burns and Plastic Surgery, Burns Unit, East Grinstead, RH19 3DZ, United Kingdom., Cubison T; Queen Victoria Hospital, Department of Burns and Plastic Surgery, Burns Unit, East Grinstead, RH19 3DZ, United Kingdom., Dheansa B; Queen Victoria Hospital, Department of Burns and Plastic Surgery, Burns Unit, East Grinstead, RH19 3DZ, United Kingdom.

Publikováno v: Burns : journal of the International Society for Burn Injuries [Burns] 2017 Dec; Vol. 43 (8), pp. 1821. Date of Electronic Publication: 2017 Oct 28.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Oncogenic RAS activity predicts response to chemotherapy and outcome in lung adenocarcinoma

Autor: Julian Downward, Philip East, Kris Sachsenmeier, Charles Swanton, Marani M, de Carné Trécesson S, David C. Hancock, Gavin Kelly, Dhruva Biswas, Creasy T

Activating mutations in the driver oncogene KRAS occur in 32% of lung adenocarcinomas, leading to more aggressive disease and resistance to therapy in preclinical studies. However, the association between KRAS mutational status and patient outcome or

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4c090f8e281184240c5841a3798337a3
https://doi.org/10.1101/2021.04.02.437896

RAS oncogenic activity predicts response to chemotherapy and outcome in lung adenocarcinoma.

Autor: East P; Bioinformatics and Biostatistics, The Francis Crick Institute, 1 Midland Road, London, NW1 1AT, UK., Kelly GP; Bioinformatics and Biostatistics, The Francis Crick Institute, 1 Midland Road, London, NW1 1AT, UK., Biswas D; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, 1 Midland Road, London, NW1 1AT, UK., Marani M; Oncogene Biology Laboratory, The Francis Crick Institute, 1 Midland Road, London, NW1 1AT, UK., Hancock DC; Oncogene Biology Laboratory, The Francis Crick Institute, 1 Midland Road, London, NW1 1AT, UK., Creasy T; Oncology Data Science, Oncology Research and Development, AstraZeneca, 200 Orchard Ridge Drive, Gaithersburg, MD, 20878, USA., Sachsenmeier K; Oncology Research and Development, AstraZeneca, 35 Gatehouse Drive, Waltham, MA, 02451, USA., Swanton C; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, 1 Midland Road, London, NW1 1AT, UK., Downward J; Oncogene Biology Laboratory, The Francis Crick Institute, 1 Midland Road, London, NW1 1AT, UK. julian.downward@crick.ac.uk.; Lung Cancer Group, Institute of Cancer Research, 237 Fulham Road, London, SW3 6JB, UK. julian.downward@crick.ac.uk., de Carné Trécesson S; Oncogene Biology Laboratory, The Francis Crick Institute, 1 Midland Road, London, NW1 1AT, UK. sophie.decarne@crick.ac.uk.

Publikováno v: Nature communications [Nat Commun] 2022 Sep 26; Vol. 13 (1), pp. 5632. Date of Electronic Publication: 2022 Sep 26.

Circulating Immune Cell and Outcome Analysis from the Phase II Study of PD-L1 Blockade with Durvalumab for Newly Diagnosed and Recurrent Glioblastoma.

Autor: Nayak L; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Standifer N; Integrated Bioanalysis, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, South San Francisco, California., Dietrich J; Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts., Clarke JL; Departments of Neurology and Neurosurgery, University of California, San Francisco, San Francisco, California., Dunn GP; Department of Neurosurgery, Washington University School of Medicine, St. Louis, Missouri., Lim M; Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, Maryland., Cloughesy T; Department of Neurology, University of California, Los Angeles, Los Angeles, California., Gan HK; Department of Medical Oncology, Austin Health, Melbourne, Australia., Flagg E; Department of Radiology, Brigham and Women's Hospital, Boston, Massachusetts., George E; Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California., Gaffey S; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Hayden J; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Holcroft C; PROMETRIKA, LLC, New York, New York., Wen PY; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Macri M; Ludwig Cancer Research, New York, New York., Park AJ; Ludwig Cancer Research, New York, New York., Ricciardi T; Ludwig Cancer Research, New York, New York., Ryan A; Ludwig Cancer Research, New York, New York., Schwarzenberger P; Ludwig Cancer Research, New York, New York., Venhaus R; Ludwig Cancer Research, New York, New York., Reyes ML; Translational Medicine Oncology, Early and Early Oncology, R&D, Gaithersburg, Maryland., Durham NM; Translational Medicine Oncology, Early and Early Oncology, R&D, Gaithersburg, Maryland., Creasy T; Translational Medicine Oncology, Early and Early Oncology, R&D, Gaithersburg, Maryland., Huang RY; Department of Radiology, Brigham and Women's Hospital, Boston, Massachusetts., Kaley T; Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York., Reardon DA; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2022 Jun 13; Vol. 28 (12), pp. 2567-2578.